The Lynx Group

Andrew Zelenetz, MD


Authored Items

Idelalisib Combined with Bendamustine/Rituximab Boosts Survival in CLL

February 2016, Vol. 5, No. 1 - ASH 2015, ASH Highlights

Idelalisib combined with bendamustine/rituximab (BR) reduced the risk of disease progression and death versus BR alone in patients with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL), according to results from a randomized, double-blind, placebo-controlled, phase 3 late-breaking trial presented at the meeting.Lead investigator Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center, [ Read More ]

Sign me up!